Mortality risk after cancer-related venous thromboembolism has decreased over the last three decades: the HUNT and Tromsø studies.

Venous thromboembolism (VTE) is a common and serious condition among cancer patients. The diagnostic and therapeutic strategies for cancer and VTE have improved during the last three decades. It remains unclear whether mortality after cancer-related VTE (CRVTE) has decreased in this period.